Introduction

Epinephrine nasal spray is a rescue medicine for anaphylaxis. It is not a treatment for day-to-day environmental allergies (rhinitis, conjunctivitis) and it does not replace long‑term therapies like allergen immunotherapy. This explainer clarifies when to use it, who should carry it, how it works, and how it differs from sublingual immunotherapy (SLIT) tablets/drops.

Last updated: October 22, 2025 (United States)

What it is (regulatory status)

In the U.S., the FDA approved neffy (epinephrine nasal spray) on August 9, 2024 for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and pediatric patients weighing ≥30 kg (≈66 lb).
On March 5, 2025, FDA expanded U.S. use to include a 1 mg dose for children 4+ years who weigh 15 to <30 kg (33 to <66 lb). See the manufacturer announcement and labeling details: ARS Pharmaceuticals release, HCP site, and prescribing info summary (1 mg/2 mg, redose at 5 minutes) via Mayo Clinic monograph.

Indication: anaphylaxis only

Use epinephrine nasal spray for the emergency treatment of severe, systemic allergic reactions (anaphylaxis). Examples of triggers include foods, insect stings, medications, and allergen immunotherapy injections. Do not wait for symptoms to worsen—give epinephrine at the first signs consistent with anaphylaxis and call 911. Guidance from allergy societies emphasizes immediate epinephrine and emergency evaluation. See AAAAI anaphylaxis page.

Recognizing anaphylaxis

Potential features (not exhaustive): trouble breathing/stridor/wheezing, throat tightness, tongue/lip swelling, hives or widespread flushing, vomiting/diarrhea or severe abdominal pain, lightheadedness/low blood pressure, sudden fatigue or collapse. If these occur after exposure—or after eating with compatible timing—treat immediately with epinephrine and activate EMS. AAAAI.

What it does—and doesn’t do

Does: rapidly delivers epinephrine systemically to reverse life‑threatening airway swelling, bronchospasm, and shock; clinical pharmacology shows blood levels and physiologic effects comparable to injection products.
Does not: treat routine nasal/eye allergy symptoms, sinus congestion, or asthma maintenance. Antihistamines and nasal steroids may help rhinitis, but they are not substitutes for epinephrine in anaphylaxis. AAAAI.

Dosing and administration (U.S.)

Ages/weights: 4+ years and ≥15 kg.
2 mg: ≥30 kg (≥66 lb) — one spray into one nostril.
1 mg: 15 to <30 kg (33 to <66 lb) — one spray into one nostril.
Redose: If there’s no improvement or symptoms worsen, give a second full device in the same nostril starting 5 minutes after the first dose.
Always call 911 after use for monitoring and further care.
Carry two devices at all times. Nasal structural conditions (e.g., polyps, recent nasal surgery) may affect absorption—discuss an auto‑injector alternative with your clinician. Sources: neffy HCP site, Mayo Clinic.

Who should carry epinephrine

People with prior anaphylaxis or at elevated risk (e.g., diagnosed food allergy with systemic reactions, Hymenoptera venom allergy, mast cell disorders, those receiving allergen immunotherapy, limited EMS access) should have epinephrine immediately available—and be trained to use it. Clinical guidance also recommends two doses be available because 16–36% of reactions may need a second dose. Cleveland Clinic review, ACAAI public guidance, EAI usage overview.

Onset and effectiveness

Epinephrine’s hemodynamic and bronchial effects begin within minutes. Pharmacokinetic/PD studies submitted to FDA demonstrated comparable epinephrine blood levels and increases in blood pressure/heart rate to injection products, supporting rapid systemic exposure when used correctly.

Safety notes

Common effects: nasal/throat irritation, jitteriness, tremor, headache, nausea; usually transient.
Special situations: underlying cardiac disease, certain arrhythmia drugs, MAOIs and other interacting medicines warrant caution; discuss with your clinician. neffy HCP site.
Nasal conditions (polyps, recent surgery) can reduce absorption—consider an injectable epinephrine option.

How epinephrine nasal spray differs from SLIT (immunotherapy tablets/drops)

Epinephrine treats emergencies; SLIT changes long‑term allergy biology. They are complementary but not interchangeable.

Dimension	Epinephrine nasal spray (neffy)	SLIT tablets/drops (immunotherapy)
Primary purpose	Immediate reversal of anaphylaxis (rescue)	Long‑term desensitization to specific aeroallergens (disease‑modifying)
When used	During a suspected anaphylactic reaction; call 911	Daily for months–years per plan
Mechanism	Alpha/beta‑agonist: raises BP, bronchodilates, reduces mucosal edema	Gradual immune tolerance to defined allergens
Onset	Minutes	Weeks to months for symptom benefit
Duration of effect	Short (minutes–hours)	Persistent benefit after 3–5 years for many patients
Treats rhinitis day‑to‑day?	No	Yes (by reducing reactivity over time)
Typical candidates	Anyone at risk of anaphylaxis (food, venom, etc.)	Patients with environmental allergies (pollen, dust mites, pet dander)
Key references		Wyndly SLIT education: Allergy shots vs SLIT, What is SLIT

Practical pointers

Prescription only; keep two in reach at all times (home, school/work, travel). Confirm weight‑appropriate device (1 mg vs 2 mg) and practice with trainer materials.
Teach family, caregivers, and schools how to recognize anaphylaxis and administer the device; maintain an action plan. AAAAI toolkit.
After any epinephrine use: call 911, bring the used device(s), and be observed for biphasic reactions.
For ongoing seasonal/environmental symptoms, consider evidence‑based longer‑term care (e.g., SLIT); epinephrine is not a daily allergy treatment.

Epinephrine nasal spray: emergency-only use (not a daily allergy treatment)